Comprehensive kinase profile of pacritinib, a nonmyelosuppressive janus kinase 2 inhibitor

Jack W. Singer, Suliman Al-Fayoumi, Haiching Ma, Rami S. Komrokji, Ruben Mesa, Srdan Verstovsek

Resultado de la investigación: Articlerevisión exhaustiva

59 Citas (Scopus)

Resumen

Pacritinib, potent inhibitor of Janus kinase 2 (JAK2), JAK2V617F, and fms-like receptor tyrosine kinase 3, is in Phase III development in myelofibrosis. Among type 1 inhibitors, pacritinib shows a lack of myelosuppression at doses that both inhibit JAK2/signal transducer and activator of transcription 3 pathway and demonstrate clinical efficacy. To elucidate these mechanisms and identify other disease targets, a kinome analysis screened 439 recombinant kinases at 100 nM pacritinib concentration. For kinases with ?50% inhibition, pacritinib was titrated from 1 to 100 nM. JAK2, JAK2V617F, FLT3, colony-stimulating factor 1 receptor, and interleukin-1 receptor-Associated kinase 1 achieved half-maximal inhibitory concentrations ?50 nM. Pacritinib did not inhibit JAK1 (82% control at 100 nM). Lack of myelosuppression may stem from inhibiting JAK2 without affecting JAK1 and reducing hematopoietic inhibitory cytokines by suppressing interleukin-1 receptor-Associated kinase 1 or colony-stimulating factor 1 receptor. The pacritinib kinome suggests therapeutic utility in acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, solid tumors, and inflammatory conditions.

Idioma originalEnglish (US)
Páginas (desde-hasta)11-19
Número de páginas9
PublicaciónJournal of Experimental Pharmacology
Volumen8
DOI
EstadoPublished - ago. 16 2016
Publicado de forma externa

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmacology (medical)

Huella

Profundice en los temas de investigación de 'Comprehensive kinase profile of pacritinib, a nonmyelosuppressive janus kinase 2 inhibitor'. En conjunto forman una huella única.

Citar esto